Buscar
Mostrando ítems 1-10 de 50
Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management
(Taylor and Francis, 2015)
Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and ...
New monoclonal antibody biosimilars approved in 2015 in Latin America: Position statement of the Latin American Forum on Biosimilars in biosimilarity, interchangeability and extrapolation of indications
(Pro Pharma Communications International, 2016-06)
Introduction: The Latin American Forum on Biosimilars (FLAB) is an annual meeting that brings together various stakeholders, including key opinion leaders, the pharmaceutical industry, academics, patients, lawyers and other ...
Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
(Springer, 2019)
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient ...
Actualización en biosimilares : una reflexión sobre la reglamentación en Colombia de los medicamentos biológicos y biosimilaresBiosimilars update, a reflection on regulations in Colombia about biological and biosimilar medicines
(Asociación Colombiana de Dermatología y Cirugía DermatológicaCentro de de Investigaciones DermatológicasBogotá, Colombia, 2021)
Expression of cetuximab biosimilar for development of Immunonanoparticle: Strategies and targets for drug delivery proposal towards treatment of prostate cancer
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2021)
A bibliometric analysis of the global research on biosimilars
(BioMed Central, 2018)
Background: Biosimilars could be a promising option to help decrease healthcare costs and expand access to treatment. There is no previous evidence of a global bibliometric analysis on biosimilars. Therefore, we aimed to ...
Revisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia.
(Universidad del RosarioMaestría en Administración en SaludFacultad de administración, 2016)
This paper aims to describe the health implications with the use of biosimilars compared with biological drugs in Colombia. Also, described the regulatory context about the use of biosimilars, recommendations and guidelines ...
Development Of Biosimilars In Brazil [desenvolvimento De Biossimilares No Brasil]
(OpenJournals Publishing, 2016)
Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
(OMICS Publishing Group, 2018-08)
Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes ...